radiobiologie;hadronthérapie;irradiateur X;noyau de carbone;efficacité biologique;chambre à vide;dosimètre;TPS;gliome malin

RECherche fondamentale en HADRONthérapie

Equipements d'excellence (EQPX)

Equipements d'excellence

Informations générales

Référence projet : 10-EQPX-0014
RST : Jean-Louis HABRAND
Etablissement Coordinateur : GIP CYCERON
Région du projet : Normandie
Discipline : 5 - Bio Med

Aide de l'ANR 1 279 770 euros
Investissement couvrant la période de février 2011 à décembre 2024

Résumé de soumission


The RECHADRON project is an equipment project part of an innovative approach in cancer therapy, hadrontherapy, being deployed on the Caen medical and scientific campus. It will actually start in 2018. Hadrontherapy is a very promising technique for the treatment of cancer, based on the use of accelerated heavy charged particles (HCPs), exhibiting a high ballistic selectivity, saving the healthy tissues and, for some of them, a biological advantage, increasing toxicity to the tumor. These advantages will be exploited by the ARCHADE project: implementation of a new generation of proton accelerator with emphasis on sparing healthy tissues, followed by a prototype of a very compact light ions accelerator, with emphasis on  toxicity to radio-resistant tumors. The RECHADRON project is an essential preliminary component in the intimate understanding of the involved and still poorly understood mechanisms underlying the original properties of HCPs at the atomic and biological levels, in particular radio-biological (cells, tissues and animals): design and commissioning of a large vacuum chamber with high sensitivity detectors for the particles cross-sections measurement generated during the interactions with matter; acquisition, development and use of an X-ray irradiator in a preclinical setting, which should allow a detailed assessment of biological effects of conventional X-rays, and serve as a reference for further studies on particle irradiation. Our biological experiments concern highly radio-resistant models (chondrocytes, glial cells and their tumor counterparts, hypoxic environment…). Since 2017, the design of the first equipment has been finalized and the realization of the vacuum chamber is about to begin. The second equipment is fully operational in cellular applications and partially in small animals, some developments being finalized soon (e.g. respiratory gating).


L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Liens utiles